APVO
APVO
NASDAQ · Biotechnology

Aptevo Therapeutics Inc

$4.23
+0.27 (+6.82%)
Financial Highlights (FY 2025)
Revenue
1.10M
Net Income
-234,853
Gross Margin
31.3%
Profit Margin
-21.4%
Rev Growth
-6.5%
D/E Ratio
0.95
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 31.3% 31.3% 31.3%
Operating Margin -24.5% -22.1% -24.1%
Profit Margin -21.4% -22.1% -19.9%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 1.10M 989.8K 1.05M
Gross Profit 343.1K 309.3K 328.2K
Operating Income -269,042 -219,026 -252,651
Net Income -234,853 -218,932 -208,731
Gross Margin 31.3% 31.3% 31.3%
Operating Margin -24.5% -22.1% -24.1%
Profit Margin -21.4% -22.1% -19.9%
Rev Growth -6.5% +19.5% +20.8%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.28M 2.80M 2.55M
Total Equity 2.39M 2.45M 2.40M
D/E Ratio 0.95 1.14 1.06
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -290,262 -298,722 -291,498
Free Cash Flow -192,766 -116,937 -167,359